Diagnostic and prognostic biomarkers in heart failure and myeloproliferative neoplasms: clinical applications and risk scores – a narrative review Authors: Ionela-Raluca Muraretu, Adriana Luminita Gurghean, Adrian Gradinaru, Mircea Bajdechi, Ilinca Savulescu-Fiedler, Anca-Maria Mihailescu, Adriana Mihaela Iliesiu Published: 2026 ABSTRACT AbstractHeart failure (HF) remains a leading cause of morbidity and mortality worldwide and frequently coexists with Philadelphia-negative myeloproliferative neoplasms (MPNs), which share thrombo-inflammatory pathways that increase cardiovascular risk. HF is often underestimated in this population, and current risk models rarely include variables specific to this complex cardio-hematologic setting. From a cardio-oncology perspective, MPNs represent a prototypical at-risk cancer population in whom chronic inflammation, clonal hematopoiesis, and cancer therapy converge to accelerate cardiovascular damage.This narrative review summarizes current evidence on diagnostic and prognostic biomarkers, imaging parameters, and validated HF and MPNs risk scores, and proposes a pragmatic hybrid framework for integrated HF-MPNs cardiovascular risk assessment. PubMed, Embase, and Web of Science were searched up to December 2025 using combinations of terms related to HF, MPNs, biomarkers, imaging, and risk models. In HF, natriuretic peptides and cardiac troponins remain central for diagnosis and short-term prognosis, whereas emerging biomarkers such as galectin-3, soluble ST2, and GDF-15 refine long-term risk prediction. Advanced imaging tools, including global longitudinal strain, left atrial strain, and cardiac magnetic resonance tissue characterization, provide prognostic value beyond the left ventricular ejection fraction. Multidimensional HF models (e.g., MAGGIC, SHFM, BCN Bio-HF, H2FPEF, 3A3B, GWTG-HF, ADHERE, and EHMRG) combine different variables to estimate mortality and hospitalization risk. In MPNs, blood counts, driver mutations (JAK2, CALR, MPL), inflammatory markers, and scores such as IPSET-thrombosis, DIPSS/DIPSS-plus, and MIPSS stratify thrombotic risk, survival, and leukemic transformation but seldom incorporate HF-specific variables.No single biomarker or score fully captures the bidirectional cardiovascular risk in patients with HF and coexisting MPNs. We propose a simple 0–8-point composite algorithm that combines key HF and MPNs variables (natriuretic peptides or troponins, HF risk scores, driver mutations, leukocytosis/thrombocytosis, LDH) to identify high-risk HF–MPNs phenotypes across ACC/AHA HF Stages A–C, suitable for structured cardio-oncology follow-up. Prospective validation of this hybrid algorithm in dedicated cardio-oncology cohorts and the development of MPNs-adapted HF guidelines are key future priorities.Keywords: Heart failure, Myeloproliferative neoplasms, Biomarkers, Risk stratification, Risk score, Cardio-oncology Introduction Heart failure (HF) is a major public health problem, affecting more than 64 million people worldwide, conferring high mortality, recurrent hospitalizations, impaired quality of life, and high healthcare costs [1, 2]. Philadelphia-negative myeloproliferative neoplasms (MPNs), represented by polycythemia vera (PV), essential thrombocythemia (ET), and primary myelofibrosis (PMF), are clonal hematologic malignancies characterized by excessive thrombotic burden and chronic inflammation that increase cardiovascular risk [3, 4]. Cardiovascular manifestations in MPNs extend beyond thrombosis to progressive HF, coronary artery disease, systemic or pulmonary hypertension (PH), valvular heart disease, and pericardial abnormalities [5, 6]. HF prevalence among patients with hematologic malignancies is around 14% [7]. Although HF and MPNs primarily involve different organ systems, they share key pathophysiological pathways, including chronic inflammation, oxidative stress, endothelial dysfunction, metabolic disturbances, high-output states, and clonal hematopoiesis [3, 8]. Epidemiological data suggest that MPNs confer approximately a two-fold higher incidence of HF compared with non-MPNs controls, while HF itself may increase incident cancer risk, highlighting a bidirectional HF-cancer relationship [9, 10]. Together, these data support the concept of a vulnerable cardio-hematologic phenotype, justify considering MPNs as at least a Stage A HF condition, and highlight the need for systematic cardiovascular monitoring [8, 11, 12]. This narrative review synthesizes evidence on diagnostic and prognostic biomarkers, imaging, and validated risk scores in patients with HF and MPNs. The aim is to propose a pragmatic framework for integrated HF-MPNs assessment, identifying evidence gaps and future research priorities. This review is positioned at the intersection of cardiology, hematology and cardio-oncology, with a specific focus on how HF risk in MPNs patients can be systematically assessed and monitored. Search strategy This narrative review is based on a structured literature search of PubMed, Embase, and Web of Science, performed up to December 2025. Combinations of keywords related to HF, MPNs, biomarkers, imaging, and risk scores were used. We primarily included clinical studies and review articles reporting the diagnostic or prognostic value of biomarkers, imaging parameters, or multivariable risk models for cardiovascular outcomes, thrombotic events, or mortality in HF and/or MPNs. No formal quality scoring or meta-analysis was performed; evidence was synthesized narratively. Heart failure in patients with myeloproliferative neoplasms: diagnostic and prognostic frameworks HF is a complex clinical syndrome driven by neuroendocrine activation, inflammation, and fibrosis, diagnosed through clinical history, physical examination, symptoms, imaging, and biomarkers. HF is classified by left ventricular ejection fraction (LVEF) into reduced (HFrEF, LVEF ≤ 40%), mildly reduced (HFmrEF, LVEF 41–49%), and preserved (HFpEF, LVEF ≥ 50%) phenotypes [13]. Diagnosis of MPNs follows WHO 2022 criteria, combining peripheral blood abnormalities, bone marrow morphology, and driver mutations (JAK2 V617F, CALR, and MPL) alongside high-molecular-risk variants (ASXL1, EZH2, and TP53) [14]. Table 1 summarizes diagnostic features and driver mutations characterizing each classical MPNs subtype. Table 1Clinical, hematologic and molecular features of classical MPNs – adapted from [15]DiseaseClinical manifestationLaboratory findingsDriver mutations (approximate frequency)PVThrombotic events, neurological symptoms, pruritus, plethora, splenomegalyElevated hematocrit (> 52% in men, > 48% in women); bone marrow panmyelosisJAK2 V617F or exon 12 (> 95%)ETThrombosis, microvascular disturbances, bleeding tendencyPlt > 450 × 109/L, normal hemoglobin and CRP, megakaryocytic hyperplasia and atypiaJAK2 (55%), CALR (25%), MPL (5%)PMFSplenomegaly, extramedullary hematopoiesis, constitutional symptoms (fatigue, weight loss, night sweats)Teardrop-shaped erythrocytes, bone marrow fibrosis (grade ≥ 1), variable cytopeniasJAK2 (55%), CALR (30%), MPL (5%)Abbreviations: CRP C-reactive protein, Plt platelets Clinical, hematologic and molecular features of classical MPNs – adapted from [15] Abbreviations: CRP C-reactive protein, Plt platelets Clinical parameters, comorbidities and clinical indicators Traditional clinical parameters guide HF risk assessment in MPNs patients. Older age and advanced New York Heart Association (NYHA) functional class are consistent predictors of mortality and rehospitalization [16]. Lower systolic blood pressure signals poorer survival through multifactorial mechanisms, including reduced cardiac output, advanced disease stage, neurohormonal dysregulation, comorbidities, and treatment effects [17–19]. MPNs-specific modifiers include age over 60 years, often linked to higher JAK2 V617F allele burden and increased thrombotic and leukemic risk, as well as prior thrombosis, the main predictor of recurrence, independent of mutations or cardiovascular risk factors [20–22]. HF etiologies in MPNs are heterogeneous, each conferring a distinct and often additive risk profile. Ischemic heart disease (50% of all HFrEF) is associated with higher mortality and HF hospitalization rates than non-ischemic etiologies. Recognizing the dominant HF mechanism (ischemic, high-output, valvular, or inflammatory) is therefore critical for individualized cardio-oncology management [8, 23, 24]. Shared comorbidities further modulate prognosis. Atrial fibrillation (AF), renal or hepatic dysfunction, diabetes mellitus, and anemia are powerful predictors of adverse outcomes in HF and significantly amplify cardiovascular and thrombotic risk in MPNs [25–27]. Anemia reduces exercise capacity, increases hospitalization and mortality in HF, but also identifies transfusion-dependent high-risk PMF. Blood transfusions create a therapeutic paradox: essential for MPNs cytopenias but predisposing to volume overload, HF decompensation, and leukemic transformation [28–30]. Spleen and liver stiffness correlate with bone marrow fibrosis degree, with spleen stiffness notably greater in PMF and PV than in ET. Serial evaluation of bone marrow fibrosis and spleen size in patients receiving JAK1/2 inhibitors can refine risk evaluation and treatment planning [3, 14, 31]. Biomarkers at the HF-MPNs interface Biological markers provide mechanistic and prognostic insight into both HF (myocardial stress, inflammation, and neurohormonal activation) and MPNs (hematologic and molecular drivers of progression). Current guidelines formally recommend only natriuretic peptides and cardiac troponins for HF [32]. In MPNs, these markers should be interpreted against a background of chronic inflammation, clonal hematopoiesis, and prothrombotic state. Hemodynamic stress and injury markers Natriuretic peptides (NPs), particularly BNP and NT-proBNP, remain the gold standard markers for HF diagnosis and risk stratification. Low levels rule out stable chronic HF (BNP < 35 pg/mL, NT-proBNP < 125 pg/mL) but require higher cut-offs in acute settings (BNP < 100 pg/mL, NT-proBNP < 300 pg/mL) [13, 33]. Each standard-deviation increase in NT-proBNP is linked to a 1.7-fold rise in major adverse cardiac events [34–36]. High-sensitivity cardiac troponins (hs-cTnT) detect subclinical myocyte injury and are associated with advanced HF, higher risk of (re)hospitalization, and mortality and may also predict new-onset HF after acute myocardial infarction [37, 38]. Admission hs-cTn > 14 ng/L predicts 12-month mortality in acute HF decompensations, while cumulative 12-months exposure (median 150 ng/L/month) offers superior risk stratification (HR 4.14 [95% CI 2.51–6.85]) [39]. In MPNs, NPs and troponins serve as adjunctive indicators of cardiovascular stress and injury. Given the increased burden of thrombosis, HF, and ischemic complications, these markers can uncover subclinical ventricular disfunction or myocardial injury when clinically suspected [8, 40]. Inflammation and fibrosis biomarkers Classical inflammatory markers such as C-reactive protein (CRP), interleukin-6 (IL-6), and tumor necrosis factor-alpha (TNF-α) are key mediators in both HF progression and MPNs pathophysiology, reflecting a shared inflammatory substrate. In HF, elevated CRP reflects systemic inflammation and poor outcomes, IL-6 impairs myocardial function and promotes hypertrophy, and TNF-α drives adverse remodeling and inflammation [41, 42]. In MPNs, elevated cytokines (e.g., IL-1, IL-2, IL-6, IL-8, IL-12, TNF-α, GM-CSF, PDGF, and VEGF) coexist with reduced anti-inflammatory mediators (e.g., IL-4, IL-10), resulting in a pronounced immune imbalance. This chronic inflammatory state drives clonal proliferation, endothelial dysfunction, thrombosis, and potentially cardiac remodeling [42–45]. Distinct cytokine profiles characterize PV, ET, and PMF and correlate with progression, thrombotic risk, and fibrotic transformation [46, 47]. Increased hs-CRP correlates with disease burden and nearly double thrombotic risk in MPNs when exceeding 3 mg/L, whereas higher pentraxin 3 appears protective [48, 49]. Galectin-3 (Gal-3) reflects cardiac inflammation and fibrosis, with levels above 13–17 ng/mL associated with disease severity and adverse outcomes. [50, 51]. In MPNs, Gal-3 overexpression in PV contributes to angiogenesis and modulation of the JAK/STAT pathway, supporting a pathogenic role [52]. Soluble ST2 (sST2) promotes cardiomyocyte apoptosis, hypertrophy, and fibrosis, thereby contributing to HF progression, and levels above 35 ng/mL predict hospitalization and mortality risk [53, 54]. In MPNs, the ST2/IL-33 axis appears biologically relevant but lacks clinical utility as a routine biomarker [55, 56]. Single biomarkers have limited accuracy, but combining NT-proBNP with Gal-3 or sST2 improve diagnosis and risk prediction of adverse outcomes [57]. Gal-3 predicts short-term mortality and rehospitalization, particularly in HFpEF, while sST2 provides prognostic information across HF phenotypes and is associated with reverse remodeling [25, 37, 58, 59]. Growth differentiation factor-15 (GDF-15) is a stress-responsive cytokine, elevated in decompensated HF and independently predicts adverse events, sometimes outperforming NT-proBNP, including in HFpEF [32, 60–62]. In MPNs, GDF-15 is upregulated in PV and ET, particularly in JAK2-V617F–positive patients, but its role remains primarily biologic rather than clinical [63]. Overall, these data support a multi-biomarker approach (NT-proBNP, hs-cTn, Gal-3, sST2, GDF-15, CRP) for HF risk assessment in MPNs, which can be layered onto standard hematologic parameters in cardio-oncology clinics. Hematologic and metabolic biomarkers Peripheral blood count abnormalities are central to MPNs diagnosis: erythrocytosis and elevated hemoglobin in PV, marked thrombocytosis of ET, and variable cytopenias in PMF [64]. Persistent leukocytosis and thrombocytosis signal poor outcome and increased thrombotic risk [65, 66]. Paradoxically, extreme thrombocytosis (≥ 1000 × 10⁹/L) increases bleeding via acquired von Willebrand syndrome [67, 68]. Simple indices derived from blood counts, including neutrophil-to-lymphocyte ratio (NLR), monocyte-to-lymphocyte ratio (MLR), and systemic immune-inflammation index (SII; platelet count × neutrophil count/lymphocyte count), are markers of systemic inflammation in MPNs and correlate with thrombotic risk, disease severity, and overall survival [69]. In PV, NLR ≥ 5 predicts venous thromboembolism [70]. In HF, NLR and SII are linked to disease severity and all-cause mortality [71, 72]. Metabolic markers also overlap: hypoalbuminemia is common in both HF and PMF and is associated with increased mortality. In HF, low albumin reflects inflammation, malnutrition, hepatorenal dysfunction, and volume overload, correlating directly with elevated CRP and inversely with total cholesterol [73–76]. The C-reactive protein-to-albumin ratio (CAR) is a powerful prognostic indicator of chronic HF [37]. Elevated lactate dehydrogenase (LDH) and uric acid reflect increased cellular turnover, oxidative stress, and endothelial dysfunction across both disease spectra, serving as markers of clonal proliferation and disease burden in MPNs and of disease progression in HF [77–79]. These hematologic and metabolic variables are particularly attractive for hybrid HF–MPNs risk models because they are routinely available and inexpensive, making them suitable for longitudinal cardio-oncology follow-up. Molecular and tumor markers Somatic driver mutations in JAK2, CALR, and MPL define the MPNs phenotypes [80]. JAK2 V617F is present in approximately 97% of PV and over 50% of ET and PMF cases and confers both diagnostic and prognostic value [81, 82]. Higher allele burden (20–50%) is associated with increased venous thromboembolism risk [83, 84]. In JAK2 V617F-negative PV, rare exon 12 mutations define a subgroup with similar features and potential evolution to secondary myelofibrosis [81, 85]. Calreticulin (CALR) mutations, seen in ET and PMF but not PV, are more prevalent in PMF and post-ET myelofibrosis, suggesting a role in fibrotic progression [86–88]. CALR-mutated patients exhibit lower leukocyte counts and hemoglobin, higher platelet, and lower arterial thrombotic risk than JAK2- or MPL-mutated cases [89, 90]. MPL mutations in exon 10 (thrombopoietin receptor) occur in a minority of ET and PMF cases and are associated with lower hemoglobin and higher transfusion dependence [91, 92]. Additional non-driver mutations modulate the effects of driver mutations, influence clonal evolution, and contribute to disease progression [87, 93]. High-molecular-risk variants (ASXL1, EZH2, SRSF2, U2AF1 Q157, and IDH1/IDH2) and a higher overall mutational load, particularly in PMF, correlate with more advanced disease, reduced survival and a higher likelihood of leukemic transformation [94, 95]. Approximately 10% of patients remain “triple-negative” but often present these adverse genotypes [93, 96]. Cancer Antigen-125 (CA-125), traditionally a tumor marker, reflects congestion, inflammation, and mechanical stress. Elevated levels are associated with HF severity and higher risk of hospitalization and mortality, especially when combined with NPs in advanced or right-sided HF [97]. Taken together, driver and high-molecular-risk mutations primarily inform hematologic prognosis but also identify subsets in whom aggressive cardiovascular risk factor control and HF surveillance are particularly warranted. Imaging-based predictors Advanced cardiac imaging, mainly echocardiography and cardiac magnetic resonance (CMR), complement biomarkers by refining HF risk stratification, particularly in HFpEF with multiple comorbidities. LVEF distinguish risk for overall mortality, cardiovascular death, and HF hospitalizations, particularly in HFrEF, but its discriminatory value is attenuated in preserved EF, so additional parameters are often needed [98, 99]. Left atrial volume index (LAVI) and left ventricular mass index (LVMI) are independently associated with adverse outcomes across HF phenotypes, with LAVI > 34 mL/m2 reflecting chronic atrial remodeling and LVMI > 115 g/m2 for men and > 95 g/m2 for women indicating LV hypertrophy [100]. Reduced left ventricular global longitudinal strain (LV-GLS less negative than −16% to −18%), reveals subtle systolic dysfunction despite normal LVEF, correlating with wall stress, fibrosis, and diastolic dysfunction [101, 102]. Strain-based indices and right heart parameters are emerging as strong prognostic markers in HFpEF, with reduced LV-GLS (less negative than −18%), impaired left atrial reservoir strain (PALS < 18–20%), and decreased TAPSE/PASP ratio (< 0.36 mm/mmHg, a marker of ventriculo-arterial uncoupling), independently predicting cardiovascular death and HF hospitalizations [103, 104]. While 2D echocardiography remains first-line, 3D-LVEF improves reproducibility for serial monitoring in cardio-oncology patients, facilitating the detection of small changes in LV function [105]. CMR offers detailed myocardial tissue characterization and is widely used for etiologic assessment and risk stratification in HF [106, 107]. In nonischemic cardiomyopathies, myocardial fibrosis detected by late gadolinium enhancement (LGE) combined with an LVEF ≤ 35% is associated with all-cause and cardiac mortality and predicts sudden cardiac death [108, 109]. Bone marrow evaluation is essential for differentiating pre-fibrotic PMF from ET and masked PV and for confirming progression to myelofibrosis. In PV patients with absolute erythrocytosis (Hb > 18.5 g/dL in men or > 16.5 g/dL in women), JAK2 mutations, and low erythropoietin, biopsy may be omitted [110–112]. Magnetic resonance imaging can quantify bone marrow infiltration in PMF, reflecting fibrosis and cellularity, and monitor therapeutic response to identify patients with hematologic progression requiring intensified cardiac screening [113]. Risk stratification frameworks Prognostic models and risk scores in HF Risk stratification is central to HF management, and several multidimensional scores predict all-cause mortality, sudden cardiac death, and cardiovascular events (see Table 2). Table 2Overview of major prognostic risk scores in heart failure patientsModel (references)HF typeVariables and scoring methodOutcomesCHRONIC HF MAGGIC risk score [114]Mixed EFDemographics, LVEF, NYHA class blood pressure renal function, comorbidities, HF therapiesAll-cause mortality; cardiovascular/HF hospitalization SHFM [115]HFrEF > HFpEFDemographics, NYHA class, blood pressure, ischemic etiology, laboratory variables, comorbidities, and HF medications/devices1-, 2-, 3-year survival BCN Bio-HF risk [116]HFrEF/HFmrEF > HFpEFClinical variables, LVEF, renal function, natriuretic peptides, hs-cTnT, and sST21-, 2-, 3-year survival H2FPEF score [117]HFpEFObesity, AF, age, antihypertensive therapy, diastolic indices (E/e’), and PASPProbability of HFpEF; HF hospitalization and cardiovascular events 3A3B score [118]HFpEFAge, albumin, anemia, BMI, natriuretic peptides, and blood urea nitrogen5-year all-cause mortality MEDIA echo score [119]HFpEFEchocardiographic indices of pulmonary pressure, right heart function, and LV filling pressure1-year cardiovascular events (death, HF hospitalization)ACUTE/DECOMPENSATED HF GWTG-HF [120]Any EFDemographics, blood pressure, renal function, serum sodium, comorbiditiesIn-hospital mortality (risk categories from < 1% to > 50%) ADHERE risk score [121]Any EFBlood urea nitrogen, systolic blood pressure, creatinineIn-hospital mortality EHMRG risk score [122]Any EFDemographics, vital signs, renal function, troponin, comorbidities, and ECG changes7-day and 30-day mortality MELD-XI [123, 124]Any EFCreatinine and bilirubin (no INR)1-, and 3-year all-cause mortalityIMAGING/ADJUNCTIVE CMR (LGE based) score [125]HFrEF/HFpEFPresence and extent of myocardial fibrosis on LGE, LVEF, LV volumes and massAll-cause mortality; sudden cardiac death (higher risk with extensive LGE and reduced LVEF)Abbreviations: GWTG-HF Get With The Guidelines-Heart Failure, LGE late gadolinium enhancement, MAGGIC Meta-Analysis Global Group in Chronic Heart Failure, MEDIA M-mode Echocardiography–Derived Index for Assessment, MELD-XI The Model for End-Stage Disease eXcluding INR, PASP pulmonary artery systolic pressure, SHFM Seattle Heart Failure Model, 3A3B Age, Albumin, Anemia, BMI, BNP, BUN Overview of major prognostic risk scores in heart failure patients Abbreviations: GWTG-HF Get With The Guidelines-Heart Failure, LGE late gadolinium enhancement, MAGGIC Meta-Analysis Global Group in Chronic Heart Failure, MEDIA M-mode Echocardiography–Derived Index for Assessment, MELD-XI The Model for End-Stage Disease eXcluding INR, PASP pulmonary artery systolic pressure, SHFM Seattle Heart Failure Model, 3A3B Age, Albumin, Anemia, BMI, BNP, BUN In acute and in-hospital settings, the Get With The Guidelines-Heart Failure (GWTG-HF), Acute Decompensated Heart Failure National Registry (ADHERE), or Emergency Heart Failure Mortality Risk Grade (EHMRG) scores support short-term risk estimation and triage decision. In chronic HF, tools such as the Seattle Heart Failure Model (SHFM), the Meta-Analysis Global Group in Chronic Heart Failure (MAGGIC) score, and the Barcelona Bio-HF (BCN Bio-HF) risk score provide long-term survival estimation and enable dynamic risk reassessment with simple clinical and laboratory inputs [126]. MAGGIC and SHFM are among the most widely validated tools for long-term outcomes in both HFrEF and HFpEF [114, 115]. More recent models enhance predictive power by incorporating biomarkers (hs-cTn, soluble ST2, NT-proBNP in BCN Bio-HF), echocardiographic parameters (the MEDIA echo score), cardiac magnetic resonance metrics (LGE-based CMR scores), or hemodynamic indices tailored to HFpEF (H2FPEF and 3A3B) [116, 119, 125]. Moreover, the H2FPEF and 3A3B scores are tailored to the HFpEF phenotype, reflecting the growing need for phenotype-specific prognostic tools [117, 118]. In patients with MPNs, these HF scores can be applied as in the general population, but their calibration may be imperfect because they do not account for MPNs-specific thrombotic, inflammatory, and hematologic factors. Prognostic models and risk scores in MPNs Prognostic scoring systems for MPNs mainly target three domains: thrombotic risk, survival, and leukemic transformation, and are widely used to guide cytoreduction, transplant decisions, and intensity of hematologic follow-up (see Tables 3, 4 and 5). These models are powerful for hematologic outcomes but largely ignore HF-specific indices, so they may miss important aspects of cardiovascular risk, particularly in patients with established or incipient HF. Table 3Risk and prognostic scoring systems for PVAxisRisk score (references)VariableRisk stratificationThrombosisClassic thrombotic risk [127, 128]Age > 60Prior thrombosisLow: age < 60 and no prior thrombosisHigh: Age ≥ 60 or prior thrombosisMFPS-PV [129]Age ≥ 60 (1 p)CVRFa (1.5 p)HR mutation for thrombosisb (1.5 p)Previous thrombosis (2 p)Low: 0–1 pIntermediate: 1.5–2.5 pHigh: ≥ 3 pSurvivalMIPSS-PV [130]Age > 67 (2 p)WBC > 15 × 109/L (1 p);Thrombosis history (1 p)SRSF2 mutation (3 p)Low: 0–1 p (mOS: 24 years);Intermediate: 2–3 p (mOS: 13.1 years)High: ≥ 4 p (mOS: 3.2 years)TransformationLeukemic/myelodysplastic risk factors [131]Age > 65WBC > 15 × 109/LAbnormal karyotype—ASXL1/SRSF2 mutationLow: no adverse featureHigh: age > 65 years, ASXL1/SRSF2 mutations, leukocytosisAbbreviations: ASXL1 Additional Sex Combs-Like 1, BCOR/BCORL1 BCL6 Corepressor/BCL6 Corepressor Like 1, CVRF cardiovascular risk factors, DNMT3A DNA (cytosine-5)-methyltransferase 3 alpha, HR high risk, MFPS-PV Multiple Factor Prognostic Score for PV, MIPSS-PV Mutation-Enhanced International Prognostic Score System for Polycythemia Vera, mOS median overall survival, SRSF2 Serine and Arginine Rich Splicing Factor 2, WBC white blood cellaHypertension, diabetes, hyperlipidemia, obesity, smokingbASXL1, DNMT3A, BCOR/BCORL1 Risk and prognostic scoring systems for PV Age > 60 Prior thrombosis Low: age < 60 and no prior thrombosis High: Age ≥ 60 or prior thrombosis Age ≥ 60 (1 p) CVRFa (1.5 p) HR mutation for thrombosisb (1.5 p) Previous thrombosis (2 p) Low: 0–1 p Intermediate: 1.5–2.5 p High: ≥ 3 p Age > 67 (2 p) WBC > 15 × 109/L (1 p); Thrombosis history (1 p) SRSF2 mutation (3 p) Low: 0–1 p (mOS: 24 years); Intermediate: 2–3 p (mOS: 13.1 years) High: ≥ 4 p (mOS: 3.2 years) Age > 65 WBC > 15 × 109/L Abnormal karyotype—ASXL1/SRSF2 mutation Low: no adverse feature High: age > 65 years, ASXL1/SRSF2 mutations, leukocytosis Abbreviations: ASXL1 Additional Sex Combs-Like 1, BCOR/BCORL1 BCL6 Corepressor/BCL6 Corepressor Like 1, CVRF cardiovascular risk factors, DNMT3A DNA (cytosine-5)-methyltransferase 3 alpha, HR high risk, MFPS-PV Multiple Factor Prognostic Score for PV, MIPSS-PV Mutation-Enhanced International Prognostic Score System for Polycythemia Vera, mOS median overall survival, SRSF2 Serine and Arginine Rich Splicing Factor 2, WBC white blood cell aHypertension, diabetes, hyperlipidemia, obesity, smoking bASXL1, DNMT3A, BCOR/BCORL1 Table 4Risk and prognostic scoring systems in ETAxisRisk score (references)VariableRisk stratificationThrombosisIPSET-thrombosis [128]Prior thrombosis (2 p)Age ≥ 60 (1 p)JAK2 V617F (2 p)CVRF (1 p)Low: 0–1 pIntermediate: 2 pHigh: ≥ 3 pRevised IPSET-thrombosis [22]Age > 60Thrombosis historyJAK2 V617FVery low: no featureLow: JAK2V617F onlyIntermediate: age > 60 yearsHigh: thrombosis history or both advanced age and JAK2V617FSurvivalIPSET [132]Age ≥ 60 (2 p)WBC ≥ 11 × 109/L (1 p)Thrombosis history (1 p)Low: 0 p (mOS: not reached)Intermediate: 1–2 p (mOS: 24.5 years)High: 3–4 p (mOS: 13.8 years)MIPSS-ET [130]Age > 60 (4 p)Male sex (1 p)WBC ≥ 11 × 109/L (1 p)SF3B1/SRSF2/TP53/U2AF1 mutation (2 p)Low: 0–1 p (mOS: 34.4 years)Intermediate: 2–5 p (mOS: 14.1 years)High: ≥ 6 p (mOS: 7.9 years)TransformationLeukemic risk [133, 134]Plt ≥ 1000 × 109/L (1 p)Abnormal karyotype (1 p)Overall incidence: 3%20-year risk of blastic transformation:Low (0 p): 3%; High (1–2 p): 13%Fibrotic progression[133, 134]MPL mutationANC ≥ 8 × 109/L12%: absence of both risk factors49%: ≥ 1 factorAbbreviations: ANC absolute neutrophil count, CVRF cardiovascular risk factors, IPSET International Prognostic Score for Essential Thrombocythemia, MIPSS-ET Mutation-Enhanced International Prognostic Score System for Essential Thrombocythemia, MPL myeloproliferative leukemia virus oncogene, mOS median overall survival, Plt platelets, WBC white blood cell Risk and prognostic scoring systems in ET Prior thrombosis (2 p) Age ≥ 60 (1 p) JAK2 V617F (2 p) CVRF (1 p) Low: 0–1 p Intermediate: 2 p High: ≥ 3 p Age > 60 Thrombosis history JAK2 V617F Very low: no feature Low: JAK2V617F only Intermediate: age > 60 years High: thrombosis history or both advanced age and JAK2V617F Age ≥ 60 (2 p) WBC ≥ 11 × 109/L (1 p) Thrombosis history (1 p) Low: 0 p (mOS: not reached) Intermediate: 1–2 p (mOS: 24.5 years) High: 3–4 p (mOS: 13.8 years) Age > 60 (4 p) Male sex (1 p) WBC ≥ 11 × 109/L (1 p) SF3B1/SRSF2/TP53/U2AF1 mutation (2 p) Low: 0–1 p (mOS: 34.4 years) Intermediate: 2–5 p (mOS: 14.1 years) High: ≥ 6 p (mOS: 7.9 years) Plt ≥ 1000 × 109/L (1 p) Abnormal karyotype (1 p) Overall incidence: 3% 20-year risk of blastic transformation: Low (0 p): 3%; High (1–2 p): 13% Fibrotic progression [133, 134] MPL mutation ANC ≥ 8 × 109/L 12%: absence of both risk factors 49%: ≥ 1 factor Abbreviations: ANC absolute neutrophil count, CVRF cardiovascular risk factors, IPSET International Prognostic Score for Essential Thrombocythemia, MIPSS-ET Mutation-Enhanced International Prognostic Score System for Essential Thrombocythemia, MPL myeloproliferative leukemia virus oncogene, mOS median overall survival, Plt platelets, WBC white blood cell Table 5Risk and prognostic scoring systems for MFAxisRisk score (references)VariableRisk stratificationThrombosisConventional risk [135]Age > 60 y, JAK2 mutation,WBC ≥ 15 × 109/LLow: absence of risk factorsHigh: JAK2 mutation + leukocytosisSurvivalDIPSS [66]/DIPSS-plus [136]DIPSS:Age ≥ 65 (1 p)Hb < 10 g/dL (2 p)WBC ≥ 25 × 109/L (1 p)Blasts ≥ 1% (1 p)Constitutional symptoms (1 p)DIPSS-plus adds:Transfusion (1 p)Platelets < 100 × 109/L (1 p)Adverse cytogenetics (1 p)DIPSS:Low: 0 p (mOS: not reached)Intermediate-1: 1–2 p (OS: 14.2 years)Intermediate-2: 3–4 p (mOS: 4 years)High: 5–6 p (mOS: 1.5 years)DIPSS-plus:Low: 0 p (mOS: 16.4 years)Intermediate-1: 1 p (OS: 6.5 years)Intermediate-2: 2–3 p (mOS: 2.9 years)High: ≥ 4 p (mOS: 1.3 years)MIPSS70-plus v2.0 [137]Hb: 9–10.9 (male)/8–9.9 (female) (1 p)Hb < 9 (male)/< 8 (female) (2 p)Blasts ≥ 2% (1 p)Constitutional symptoms (2 p)Absence of CALR type-1 mutations (2 p)1 HMR mutation (2 p) ≥ 2 HMR mutations (3 p)Unfavorable karyotype (3 p)VHR karyotype (4 p)Very low: 0 p (mOS: not reached)Low: 1–2 p (mOS: 10.3 years)Intermediate: 3–4 p (mOS:7 years)High: 5–8 p (mOS: 3.5 years)Very high: ≥ 9 (mOS: 1.8 years)TransformationLeukemic risk model [138]Age > 70 (1 p)Anemia (1 p)Blasts ≥ 3% (2 p)IDH1 (3 p), SRSF2 (2 p), ASXL1 (1 p)Low: 0–1 p (LE: 8%);Intermediate: 2–6 p (LE: 17%)High: 7–8 p (LE: 57%)MYSEC-PM [139]Age (0.15a)Hb < 11 g/dL (2 p)Plt < 150 × 109/L (1 p)Blasts ≥ 3% (2 p)Constitutional symptoms (1 p)CALR-unmutated (2 p)Final riskbLow (mOS: not reached)Intermediate-1 (mOS: 9.3 years)Intermediate-2 (mOS: 4.4 years)High (mOS: 2 years)HMR (high molecular risk): Presence of a mutation in any of the following genes: ASXL1, EZH2, SRSF2, U2AF1 Q157, or IDH1/2Unfavorable karyotype: complex karyotype or one or two abnormalities including + 8, 7/7q −, i(17q), 5/5q −, 12p −, inv (3), or 11q23 rearrangementsVHR (very high-risk) karyotype: single/multiple abnormalities of − 7, i(17q), inv (3)/3q21, 12p −/12p11.2, 11q −/11q23, or other autosomal trisomies not including + 8/+ 9 (e.g., + 21, + 19)Abbreviations: DIPSS Dynamic International Prognostic Scoring System, DIPSS-plus Dynamic International Prognostic Scoring System plus, Hb hemoglobin, IDH1/2 isocitrate dehydrogenase ½, IPSS International Prognostic Scoring System, IPSS-R Revised International Prognostic Scoring System, LE leukemic events, MIPSS70 Mutation-Enhanced International Prognostic Scoring System for patients ≤ 70 years, MIPSS70-plus v2.0 Mutation-Enhanced International Prognostic Scoring System for patients ≤ 70 years plus version 2.0, mOS median overall survival, MYSEC-PM Myelofibrosis Secondary Prognostic Model, Plt platelet count, U2AF1 U2 small nuclear RNA auxiliary factor 1, WBC white blood cell countaAge contributes to the overall score through specific points allocated in the nomogrambThe MYSEC-PM nomogram is applied to determine the final risk category Risk and prognostic scoring systems for MF Age > 60 y, JAK2 mutation, WBC ≥ 15 × 109/L Low: absence of risk factors High: JAK2 mutation + leukocytosis DIPSS [66]/ DIPSS-plus [136] DIPSS: Age ≥ 65 (1 p) Hb < 10 g/dL (2 p) WBC ≥ 25 × 109/L (1 p) Blasts ≥ 1% (1 p) Constitutional symptoms (1 p) DIPSS-plus adds: Transfusion (1 p) Platelets < 100 × 109/L (1 p) Adverse cytogenetics (1 p) DIPSS: Low: 0 p (mOS: not reached) Intermediate-1: 1–2 p (OS: 14.2 years) Intermediate-2: 3–4 p (mOS: 4 years) High: 5–6 p (mOS: 1.5 years) DIPSS-plus: Low: 0 p (mOS: 16.4 years) Intermediate-1: 1 p (OS: 6.5 years) Intermediate-2: 2–3 p (mOS: 2.9 years) High: ≥ 4 p (mOS: 1.3 years) Hb: 9–10.9 (male)/8–9.9 (female) (1 p) Hb < 9 (male)/< 8 (female) (2 p) Blasts ≥ 2% (1 p) Constitutional symptoms (2 p) Absence of CALR type-1 mutations (2 p) 1 HMR mutation (2 p) ≥ 2 HMR mutations (3 p) Unfavorable karyotype (3 p) VHR karyotype (4 p) Very low: 0 p (mOS: not reached) Low: 1–2 p (mOS: 10.3 years) Intermediate: 3–4 p (mOS:7 years) High: 5–8 p (mOS: 3.5 years) Very high: ≥ 9 (mOS: 1.8 years) Age > 70 (1 p) Anemia (1 p) Blasts ≥ 3% (2 p) IDH1 (3 p), SRSF2 (2 p), ASXL1 (1 p) Low: 0–1 p (LE: 8%); Intermediate: 2–6 p (LE: 17%) High: 7–8 p (LE: 57%) Age (0.15a) Hb < 11 g/dL (2 p) Plt < 150 × 109/L (1 p) Blasts ≥ 3% (2 p) Constitutional symptoms (1 p) CALR-unmutated (2 p) Final riskb Low (mOS: not reached) Intermediate-1 (mOS: 9.3 years) Intermediate-2 (mOS: 4.4 years) High (mOS: 2 years) HMR (high molecular risk): Presence of a mutation in any of the following genes: ASXL1, EZH2, SRSF2, U2AF1 Q157, or IDH1/2 Unfavorable karyotype: complex karyotype or one or two abnormalities including + 8, 7/7q −, i(17q), 5/5q −, 12p −, inv (3), or 11q23 rearrangements VHR (very high-risk) karyotype: single/multiple abnormalities of − 7, i(17q), inv (3)/3q21, 12p −/12p11.2, 11q −/11q23, or other autosomal trisomies not including + 8/+ 9 (e.g., + 21, + 19) Abbreviations: DIPSS Dynamic International Prognostic Scoring System, DIPSS-plus Dynamic International Prognostic Scoring System plus, Hb hemoglobin, IDH1/2 isocitrate dehydrogenase ½, IPSS International Prognostic Scoring System, IPSS-R Revised International Prognostic Scoring System, LE leukemic events, MIPSS70 Mutation-Enhanced International Prognostic Scoring System for patients ≤ 70 years, MIPSS70-plus v2.0 Mutation-Enhanced International Prognostic Scoring System for patients ≤ 70 years plus version 2.0, mOS median overall survival, MYSEC-PM Myelofibrosis Secondary Prognostic Model, Plt platelet count, U2AF1 U2 small nuclear RNA auxiliary factor 1, WBC white blood cell count aAge contributes to the overall score through specific points allocated in the nomogram bThe MYSEC-PM nomogram is applied to determine the final risk category Polycythemia vera In PV, arterial and venous thrombosis are the leading cause of morbidity and mortality [140]. Age above 60 years and history of thrombosis are the strongest predictors of vascular events [141–143]. The Multiple Factor Prognostic Score for PV (MFPS-PV) refines thrombotic risk stratification by incorporating cardiovascular risk factors and high-risk mutations [129]. For survival, Mutation-Enhanced International Prognostic Scoring System for PV (MIPSS-PV) adds molecular variables such as SRSF2, guiding cytoreduction [130, 143]. Leukemic transformation, less common than in PMF, links to age, leukocytosis, abnormal karyotypes, and SRSF2/IDH2 mutations, particularly in patients exposed to alkylating agents or radiophosphorus therapy [131, 144]. The main PV scores and their variables are summarized in Table 3. Essential thrombocythemia ET generally has the most favorable prognosis among classical MPNs, with median survival approximately 18–20 years, though thrombotic events dominate morbidity and mortality [8, 145]. The International Prognostic Score for Thrombosis in ET (IPSET-Thrombosis) and revised IPSET-Thrombosis (r-IPSET-T) integrate clinical and molecular factors to refine thrombotic risk prediction and guide cytoreduction versus antiplatelet therapy [22, 128]. For survival, International Prognostic Score for ET (IPSET-Survival) and Mutation-Enhanced IPSS for ET (MIPSS-ET) refine risk by integrating inflammatory markers and high-molecular-risk mutations (SF3B1/SRSF2/TP53/U2AF1) [130, 132, 146]. Although leukemic and fibrotic transformation are uncommon in ET over 10–15 years, they are associated with older age, extreme thrombocytosis, anemia, leukocytosis, exposure to alkylating agents and adverse genotypes (e.g., ASXL1, SRSF2, and IDH1/2), with MPL mutations and elevated neutrophil counts predicting fibrotic progression (Table 4) [133, 134, 147, 148]. Primary myelofibrosis PMF is the most aggressive form of classical MPNs, with a median overall survival of 6 years, marked by high symptom burden, risk of leukemic transformation, and complications [8, 149]. Table 5 summarizes some of the most widely used risk scores. Thrombotic events are less frequent than in PV but the risk increases with older age, JAK2 mutation status, and leukocytosis [135]. Survival prognostication has evolved from purely clinical scores, such as the International Prognostic Scoring System (IPSS) and the Dynamic IPSS (DIPSS)/DIPSS-Plus, which dynamically reassess risk by giving more weight to anemia, thrombocytopenia, transfusion dependency, and adverse cytogenetics [66, 136, 149]. More recently molecularly integrated models such as MIPSS70 and MIPSS70 + v2.0, combine clinical variables with high-molecular-risk mutations and karyotype abnormalities, particularly to guide transplant decisions [150, 151]. Leukemic transformation occurs in 10%−20% at 10-year, with post-transformation survival of 3–4 months [144, 152]. Key predictors include a higher blast percentage, cytopenias, unfavorable cytogenetics, triple-negative status and mutations such as ASXL1, SRSF2, RUNX1, CEBPA, and SH2B3 [30, 94]. The Myelofibrosis Secondary to PV/ET Prognostic Model (MYSEC-PM) is specifically designed for secondary myelofibrosis [139]. Treatment-response scores for ruxolitinib and transplant-specific models, refine prognosis in advanced disease in which optimization of cardiovascular status is crucial [153, 154]. Although these PV, ET and PMF scores were not developed with HF endpoints in mind, high-risk categories often coincide with older age, heavy symptom burden, inflammatory activation, anemia or transfusion dependence and adverse genotypes, all of which may amplify HF risk and therefore represent natural anchors for integrating cardiovascular biomarkers and imaging in our hybrid HF–MPNs framework. Clinical implications ACC/AHA HF stages and pathophysiological mechanisms in MPNs-HF The 2022 AHA/ACC/HFSA guidelines define HF as a continuum from Stage A (at risk for HF without structural disease or elevated biomarkers), Stage B (pre-HF: structural disease, elevated filling pressures, or persistently elevated natriuretic peptides/troponins without symptoms), Stage C (symptomatic HF), to Stage D (advanced/refractory HF) [12]. In a large claims database, patients with MPNs had a higher incidence of congestive HF than non-MPNs controls (9.27 vs 3.70 per 1000 person-years; adjusted HR 1.64) [10]. In observational cohorts, patients with MPNs and concomitant HF experience higher in-hospital mortality and 90-day cardiovascular readmission rates than non-MPNs patients, with ET and especially myelofibrosis conferring greater 90-day CV and HF-related readmission risk than PV [155]. Chronic systemic inflammation, oxidative stress, and endothelial dysfunction promote diffuse myocardial fibrosis, diastolic dysfunction, and HFpEF, whereas microvascular dysfunction and accelerated atherosclerosis increase the burden of ischemic HFrEF [45, 156, 157]. High-output states (8% of MPNs cases) driven by anemia, hypervolemia, and splenomegaly impose LV stress, predisposing to eccentric remodeling and HF progression [8, 158]. In addition, pulmonary hypertension related to chronic thromboembolic disease or elevated pulmonary vascular resistance may aggravate right HF [159, 160]. Cancer therapies, including cytoreductive agents and JAK inhibitors, bidirectionally modulate risk: attenuating inflammatory signaling and splenomegaly they may mitigate HF risk, but potential off-target cardiotoxicity, fluid retention, and anemia can precipitate HF decompensation, particularly in patients with pre-existing Stage C disease [8, 161, 162]. Taken together, these data support regarding MPNs as a high-risk Stage A HF condition, as chronic thrombo-inflammatory activation, endothelial dysfunction, oxidative stress, anemia/high-output states, and treatment effects create a persistent substrate for structural and functional myocardial injury, mirroring ACC/AHA Stage A criteria despite absent overt disease. Risk stratification and monitoring Patients with MPNs represent a high-risk cardio-oncology population requiring systematic baseline cardiovascular assessment before initiating cytoreductive therapy or JAK inhibitors. Although MPNs-specific data are limited, information is extrapolated from the ESC 2022 Cardio-Oncology Guidelines, that recommend a comprehensive baseline evaluation, including history, ECG, echocardiography with GLS, natriuretic peptides, and cardiac troponins, for all patients starting potentially cardiotoxic cancer therapies [163]. Baseline echocardiography frequently reveals early diastolic dysfunction even in asymptomatic patients, particularly those with JAK2 V617F mutations. This initial assessment identifies patients who may benefit from preventive guideline-directed medical therapy (GDMT), such as sodium-glucose cotransporter-2 (SGLT2) inhibitors, prior to disease-modifying MPNs treatments [160, 164]. Dynamic risk assessment during JAK inhibitor therapy (every 3–6 months) includes NT-proBNP and hs-cTnT monitoring to detect subclinical cardiotoxicity early. Trends in the levels of inflammatory markers (CRP and IL-6) are correlated with both thrombotic risk and HF decompensation [165, 166]. Figure 1 illustrates the main diagnostic and prognostic biomarkers in HF and MPNs patients, highlighting metabolic–inflammatory overlaps for cardio-oncology follow-up. Integrated biomarker profile in patients with HF and MPNs. See abbreviations list Although MPNs-specific echocardiographic GLS data remain limited, frequent subclinical diastolic dysfunction and emerging strain data from high-risk cardio-oncology cohorts support its utility in MPNs patients. GLS surveillance is particularly valuable in preserved LVEF cases, where strain reduction typically precedes systolic dysfunction. In a prospective MPNs cohort with PH-associated HFpEF, right ventricle-GLS < − 19% and LV-GLS identified subclinical dysfunction despite normal LVEF, demonstrating superior mortality prediction (HR 3.2, p = 0.003 independent of PASP) versus conventional TAPSE/S′, enabling Stage B detection to prevent HF progression [167]. Therapeutic decision-making Optimal HF management in MPNs remains poorly defined. National Comprehensive Cancer Network guidelines promote CV risk factors control but lack HF recommendations [110]. While JAK inhibitors show promise, HF likely arises from shared pathophysiology rather than cardiotoxicity [9, 163]. In the absence of specific HF-MPNs guidelines, the implementation of integrated risk stratification and therapeutic strategies necessitates a cardio-hemato-oncology multidisciplinary team (MDT) approach—as endorsed by the 2022 ESC Cardio-Oncology Guidelines—to optimize GDMT (e.g., SGLT2i ± ARNI), cytoreductive therapies (ruxolitinib/hydroxyurea), and serial monitoring of NT-proBNP/GLS, thereby minimizing HF decompensations in this high-risk population [163, 168]. The clinical challenge is balancing antithrombotic therapy against bleeding risk while optimizing HF management. No formal guidelines exist for managing new-onset or decompensated HF during cytoreductive or JAK-inhibitor therapy in MPNs. The strategies outlined below represent a pragmatic approach extrapolated from trial data and expert consensus. In patients with MPNs requiring cytoreduction, baseline HF risk stratification using the H2FPEF score may guide GDMT titration. For example, patients with H2FPEF scores ≥ 6 warrant SGLT2i initiation regardless of LVEF because of the demonstrated benefit on HFpEF [169]. Additionally, the potential anti-inflammatory effects of SGLT2i in HF patients may be relevant to MPNs pathophysiology [170]. SGLT2 inhibitors require cautious use because of their hematologic effects. Small cohort studies report consistent hematocrit elevation post-initiation, with thrombosis observed in PV, but potential anemia benefit in myelofibrosis. Close hematocrit monitoring is essential before and after SGLT2i initiation [160, 171]. Conversely, extreme thrombocytosis (> 1000 × 10⁹/L) mandates temporary aspirin interruption to avoid acquired von Willebrand syndrome [172]. Moreover, traditional CV risk factors such as hypertension, diabetes, and smoking remain clinically relevant (particularly in PV), despite their omission from certain revised thrombotic models [173]. In addition, AF adds a significant cardiovascular burden in MPNs, and is linked to an increased risk of HF hospitalization, cardiovascular death, and thrombotic events, underscoring the need for MPNs-adapted or hybrid scoring systems, as traditional scores such as the CHA₂DS₂-VASc score may underestimate the true risk [174]. When HF decompensation occurs during cytoreductive or JAK-inhibitor therapy (often precipitated by ruxolitinib-induced anemia, thrombocytopenia, fluid retention, or volume shifts), clinicians must weigh interrupting disease-modifying treatment against cardiotoxic contribution. Temporary dose reduction/interruption with rechallenge may be appropriate with clear temporal association and acceptable thrombotic risk [175, 176]. Conversely, when HF stems primarily from uncontrolled MPNs-related inflammation, hyperviscosity (leukocytosis/thrombocytosis), or severe splenomegaly, maintaining or even optimizing MPNs-directed therapy is crucial for long-term cardiovascular stability, as JAK inhibitors reduce thromboembolic events and hydroxyurea controls arterial thrombosis despite manageable hematologic toxicity [161, 177]. Future directions. Hybrid risk stratification: practical algorithm Patients with MPNs and HF represent a unique cardio-hematologic population where standard CV risk models underestimate disease burden. The H2FPEF score, validated in HFpEF, shows promise in MPNs, as higher scores correlate with increased rates of HF hospitalization. Hematologic factors such as leukocytosis and splenomegaly, indicate a direct contribution of the disease to cardiac dysfunction [164, 178]. As no validated HF-MPNs risk model currently exists, we propose a pragmatic framework combining general HF prognostic scores (MAGGIC for mortality prediction or H2FPEF for HFpEF diagnosis/prognosis), along with MPNs-specific thrombotic scores, and hematologic parameters (leukocyte/platelet counts, JAK2 V617F presence/allele burden, LDH) [179–182]. The proposed algorithm (Fig. 2) outlines personalized management requiring prospective validation but aligns with ESC cardio-oncology principles of integrated risk assessment [163, 165]. Proposed risk statification algorithm (0-8p). See abbreviations list This 0–8 point composite algorithm is designed to be applicable to all MPNs patients (ET/PV/MF) across AHA/ACC Stages A-C, irrespective of HF diagnosis, but it should currently be regarded as conceptual, pending prospective validation. Stage D (refractory end-stage HF) patients require specialized advanced therapies beyond this framework [12]. Scoring rationale: each independent risk factor contributes 1 point, reflecting established 2–3 × hazard ratios from the cardio-oncology/MPNs literature [8, 163, 173]. The simple additive model facilitates bedside use without software, generating actionable stratification (intensified surveillance, prevention, and therapy optimization) pending prospective validation. Unlike prior HFpEF frameworks, this algorithm explicitly incorporates Stages A and B, capturing asymptomatic MPNs patients with subclinical cardiac involvement for early preventive strategies.​ Moreover, prospective studies are needed to assess whether early GDMT or anti-inflammatory therapies (e.g., colchicine, canakinumab) reduce cardiovascular events in high-risk MPNs subsets [183]. Antifibrotic agents targeting lysyl oxidase-like 2 (LOXL2), which cross-links collagen and promotes stiffness, show promise for MPNs-associated HF across ACC/AHA Stages A–C: LOXL2 inhibition reduces interstitial fibrosis, improves diastolic function, and prevents chamber dilatation in stress-induced HF models, without affecting hypertrophy [184]. Limitations This is a narrative review, so the evidence is heterogeneous and subject to selection bias. Most data derive from separate HF or MPNs cohorts rather than patients with both conditions, and the proposed hybrid algorithm remains hypothesis-generating. External prospective validation will be required before clinical implementation. Integration of artificial intelligence and machine learning (ML) with serial biomarkers, imaging, and hematologic data may enable more dynamic HF risk prediction in MPNs, but current ML models have not yet clearly outperformed traditional risk scores and still require careful validation and clinical integration; establishing multidisciplinary cardio-hematology clinics will be crucial to translate these tools into practice [185–187]. Conclusions This review highlights that no single biomarker or risk score adequately captures the bidirectional cardio-hematologic risk in MPNs-HF patients. Integrating established HF tools (NT-proBNP/troponins, H2FPEF/MAGGIC) with MPNs-specific parameters (JAK2 mutation/burden) within our proposed hybrid algorithm (Fig. 2) may facilitate more comprehensive risk stratification across ACC/AHA Stages A–C. Prospective validation in dedicated cardio-oncology cohorts remains essential to refine this framework and establish MPNs-adapted HF guidelines. Multidisciplinary cardio-hemato-oncology teams, empowered by serial biomarker/imaging surveillance, represent the optimal pathway to mitigate HF progression, optimize GDMT alongside cytoreductive therapies, and improve survival in this vulnerable population. Acknowledgements Publication of this paper was supported by the University of Medicine and Pharmacy Carol Davila, through the institutional program Publish not Perish. Abbreviations Age, albumin, anemia, BMI, BNP, BUN Acute Decompensated Heart Failure National Registry Atrial fibrillation Absolute neutrophil count Angiotensin receptor-neprilysin inhibitor Additional Sex Combs-Like 1 Barcelona Bio-Heart Failure BCL6 Corepressor/BCL6 Corepressor Like 1 Body mass index B-type natriuretic peptide Calreticulin C-reactive protein-to-albumin ratio CCAAT/enhancer-binding protein alpha Cardiac magnetic resonance C-reactive protein Cardiovascular Cardiovascular risk factors Dynamic International Prognostic Scoring System DNA cytosine-5-methyltransferase 3 A Early diastolic mitral inflow velocity to mitral annular early diastolic velocity ratio Ejection fraction Emergency Heart Failure Mortality Risk Grade Essential thrombocythemia Enhancer of Zeste Homolog 2 Galectin-3 Growth differentiation factor-15 Guideline-directed medical therapy Global longitudinal strain Granulocyte–macrophage colony-stimulating factor Get With The Guidelines-Heart Failure Hemoglobin Heart failure Heart failure with reduced ejection fraction Heart failure with mildly reduced ejection fraction Heart failure with preserved ejection fraction High-sensitivity cardiac troponin T Heart Failure with Preserved Ejection Fraction Isocitrate dehydrogenase ½ Interferon gamma-induced protein 10 International Prognostic Score for Essential Thrombocythemia Janus kinase 2 Left atrial volume index Late gadolinium enhancement Lysyl oxidase-like 2 Left ventricle Left ventricular ejection fraction Left ventricular mass index Meta-Analysis Global Group in Chronic Heart Failure Multidisciplinary team M-mode Echocardiography-Derived Index for Assessment Model for End-Stage Liver Disease excluding INR Multiple Factor Prognostic Score for PV Mutation-Enhanced International Prognostic Scoring System Machine learning Monocyte-to-lymphocyte ratio Myeloproliferative leukemia virus oncogene Myeloproliferative neoplasms Median overall survival Neutrophil-to-lymphocyte ratio N-terminal pro-B-type natriuretic peptide New York Heart Association Left atrial reservoir strain Pulmonary artery systolic pressure Platelet-derived growth factor Pulmonary hypertension Platelets Primary myelofibrosis Polycythemia vera Revised International Prognostic Score for Thrombosis in Essential Thrombocythemia Runt-related transcription factor 1 Systolic blood pressure Splicing factor 3b subunit 1 Sodium-glucose cotransporter-2 inhibitor SH2B adaptor protein 3 Seattle Heart Failure Model Systemic immune-inflammation index Serine and Arginine Rich Splicing Factor 2 Soluble Suppression of Tumorigenicity 2 Tricuspid annular plane systolic excursion Tumor necrosis factor-alpha U2 small nuclear RNA auxiliary factor 1 Vascular endothelial growth factor Venous thromboembolism Upper limit of normal White blood cell Authors’ contributions Ionela-Raluca Muraretu (I.-R.M.) conceptualized the study, designed the search strategy alongside A.-L.G., conducted the primary literature review, drafted the initial manuscript focusing on HF biomarkers and risk scores, created figures, and managed revisions. Adriana-Luminita Gurghean (A.-L.G.), corresponding author, co-conceived the article, led MPNs content development, reviewed and revised the draft extensively, and validated data. Adrian Gradinaru (A.G.) analyzed clinical parameters, comorbidities, and imaging sections, contributing substantial review and editing. Mircea Bajdechi (M.B.) and Ilinca Savulescu-Fiedler (I.S.-F.) contributed to the literature review, completed key sections, and provided manuscript review. Anca-Maria Mihailescu (A.-M.M.) curated tables, organized data, and offered critical revisions. Adriana Mihaela Iliesiu (A.M.I.), as senior author, supervised the work, edited the final version, and approved submission. All authors reviewed the manuscript and approve its final form. Funding No funding was received. Data availability No datasets were generated or analysed during the current study. Declarations Ethics approval and consent to participate Not applicable. This article is a narrative review based on previously published studies and does not involve new data collected from human participants or animals. Consent for publication Not applicable. Competing interests The authors declare no competing interests. Footnotes Publisher’s Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations. References Associated Data Data Availability Statement No datasets were generated or analysed during the current study.